TOP TEN perturbations for 39979_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39979_at
Selected probe(set): 205620_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39979_at (205620_at) across 6672 perturbations tested by GENEVESTIGATOR:

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):-2.9990864
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

uterine/pelvic pathology study 2 (late se MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):-2.9533844
Number of Samples:2 / 6
Experimental uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (early se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):2.9386501
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (15d)

Relative Expression (log2-ratio):-2.514801
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.

uterine/pelvic pathology study 2 (mid-se MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):2.4658413
Number of Samples:14 / 2
Experimental uterine/pelvic pathology study 2 (mid-se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the mid-secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

HCC study 23 (portal vein infiltration) / adjacent liver tissue

Relative Expression (log2-ratio):-2.3475208
Number of Samples:3 / 10
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample

Relative Expression (log2-ratio):-2.2562828
Number of Samples:3 / 6
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2)
Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (PBS) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

HCC study 23 (portal vein infiltration) / HCC study 23 (no portal vein infiltration)

Relative Expression (log2-ratio):-2.2324095
Number of Samples:3 / 7
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control HCC study 23 (no portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) without portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):2.1946392
Number of Samples:15 / 2
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-2.1393404
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.